Skip to content

A Two-Group Study to Test the Effects of an Ayurveda Treatment on Bone Health in Postmenopausal Women.

A Two-Arm Longitudinal Randomized Control Trial to Evaluate the Bone Protective Role of an Ayurveda Formulation in Postmenopausal Females. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083085
Enrollment
220
Registered
2025-03-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R688- Other general symptoms and signs

Interventions

None listed

Sponsors

AyushICMR AdvanAlACIHR at AIIMS under Extramural Program
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: postmenopausal females aged 50-70 years, diagnosed with osteoporosis as per World Health Organization (WHO) criteria, (BMD that lies - 2.5 standard deviation or more below the average value for young healthy women

Exclusion criteria

Exclusion criteria: woman suffering from secondary osteoporosis such as inflammatory joint or bowel disorders, current glucocorticoid therapy, chronic kidney disease, malabsorption, untreated endocrine disorders

Design outcomes

Primary

MeasureTime frame
Change in Bone Mineral Density (BMD) at the lumbar spine, femoral neck, and total hip measured using Dual-Energy X-ray Absorptiometry (DEXA). Timepoint: Baseline (Week 0) Before starting the intervention At 24 Weeks (End of Treatment) After completion of the 6-month intervention

Secondary

MeasureTime frame
This research is designed to provide tailored insights into the potential of Ayurveda formulations for enhancing bone health in menopausal & geriatric females. Positive outcomes could lead to targeted interventions that address the specific needs of these populations, improving their overall quality of life & reducing the burden of osteoporosis- related complications.Timepoint: Time Points Baseline, 12 Weeks (Mid of Treatment), 24 Weeks (End of Treatment).

Countries

India

Contacts

Public ContactDr Ashok Kumar Ahirwar

AIIMS, Delhi

drashokahirwar@aiims.edu9654210832

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026